Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature

被引：11
|
作者：
Tolcher, Anthony W.
Alley, Evan W.
Chichili, Guru
Baughman, Jan E.
Moore, Paul A.
Bonvini, Ezio
Vasselli, James Robert
Wigginton, Jon M.
Powderly, John D.
机构：
[1] START San Antonio, San Antonio, TX USA
[2] Univ Pennsylvania, Philadelphia, PA USA
[3] MacroGenics Inc, Rockville, MD USA
[4] MacroGenics Inc, Bethesda, MD USA
[5] MacroGenics Inc, Frederick, MD USA
[6] Carolina BioOncol Inst, Huntersville, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS3105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3105
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Kim Kramer
    Neeta Pandit-Taskar
    Brian H. Kushner
    Pat Zanzonico
    John L. Humm
    Ursula Tomlinson
    Maria Donzelli
    Suzanne L. Wolden
    Sophia Haque
    Ira Dunkel
    Mark M. Souweidane
    Jeffrey P. Greenfield
    Satish Tickoo
    Jason S. Lewis
    Serge K. Lyashchenko
    Jorge A. Carrasquillo
    Bae Chu
    Christopher Horan
    Steven M. Larson
    Nai-Kong V. Cheung
    Shakeel Modak
    Journal of Hematology & Oncology, 15
  • [32] Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
    Kramer, Kim
    Pandit-Taskar, Neeta
    Kushner, Brian H.
    Zanzonico, Pat
    Humm, John L.
    Tomlinson, Ursula
    Donzelli, Maria
    Wolden, Suzanne L.
    Haque, Sophia
    Dunkel, Ira
    Souweidane, Mark M.
    Greenfield, Jeffrey P.
    Tickoo, Satish
    Lewis, Jason S.
    Lyashchenko, Serge K.
    Carrasquillo, Jorge A.
    Chu, Bae
    Horan, Christopher
    Larson, Steven M.
    Cheung, Nai-Kong V.
    Modak, Shakeel
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [33] PHASE 1 STUDY OF INTRAVENTRICULAR 131I-OMBURTAMAB TARGETING B7H3 (CD276)-EXPRESSING CNS MALIGNANCIES
    Modak, Shakeel
    Pandit Taskar, Neeta
    Kushner, Brian
    Zanzonico, Pat
    Humm, John
    Donzelli, Maria
    Lewis, Jason
    Lyashchenko, Serge
    Chu, Bae
    Larson, Stephen
    Cheung, Nai Kong
    Kramer, Kim
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [34] STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors
    Pinto, Navin
    Albert, Catherine M.
    Taylor, Mallory R.
    Ullom, Heidi B.
    Wilson, Ashley L.
    Huang, Wenjun
    Wendler, Jason
    Pattabhi, Sowmya
    Seidel, Kristy
    Brown, Christopher
    Gustafson, Joshua A.
    Rawlings-Rhea, Stephanie D.
    Cheeney, Safia H. E.
    Burleigh, Katelyn
    Gustafson, Heather H.
    Orentas, Rimas J.
    Vitanza, Nicholas A.
    Gardner, Rebecca A.
    Jensen, Michael C.
    Park, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (35)
  • [35] Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
    Aggarwal, Charu
    Prawira, Amy
    Antonia, Scott
    Rahma, Osama
    Tolcher, Anthony
    Cohen, Roger B.
    Lou, Yanyan
    Hauke, Ralph
    Vogelzang, Nicholas
    Zandberg, Dan P.
    Kalebasty, Arash Rezazadeh
    Atkinson, Victoria
    Adjei, Alex A.
    Seetharam, Mahesh
    Birnbaum, Ariel
    Weickhardt, Andrew
    Ganju, Vinod
    Joshua, Anthony M.
    Cavallo, Rosetta
    Peng, Linda
    Zhang, Xiaoyu
    Kaul, Sanjeev
    Baughman, Jan
    Bonvini, Ezio
    Moore, Paul A.
    Goldberg, Stacie M.
    Arnaldez, Fernanda, I
    Ferris, Robert L.
    Lakhani, Nehal J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (04)
  • [36] B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy
    Siji Chen
    Shenghua Zhan
    Sisi Ding
    Qiange Zhang
    Hanqin Xuan
    Xueguang Zhang
    Lei Cao
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 16609 - 16621
  • [37] B7-H3 and CD47 co-expression in gastric cancer is a predictor of poor prognosis and potential targets for future dual-targeting immunotherapy
    Chen, Siji
    Zhan, Shenghua
    Ding, Sisi
    Zhang, Qiange
    Xuan, Hanqin
    Zhang, Xueguang
    Cao, Lei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (18) : 16609 - 16621
  • [38] A phase 1, first-in-human, open-label, dose escalation study of MGD013, a bispecific DART® protein binding PD-1 and LAG-3 in patients with unresectable or metastatic neoplasms
    Shankar, Sadhna
    Patel, Manish
    Blumenschein, George
    Hamilton, Erika
    Luke, Jason
    Mohs, Ross La-Motte
    Shah, Kalpana
    Adali-Piston, Lisa
    Johnson, Syd
    Bonivini, Ezio
    Moore, Paul
    Wigginton, Jon
    Vasselli, Jim
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [39] PD-1, PD-L1, and B7-H3 expression in Human Immunodeficiency Virus (HIV) infected patients with aerodigestive (AD) cancers (CA).
    Scilla, Katherine Ann
    Heath, Jonathon
    Ioffe, Olga B.
    Cellini, Ashley L.
    Edelman, Martin J.
    Zandberg, Dan Paul
    Riedel, David
    Feliciano, Josephine Louella
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer
    Zhou, Zhuoxin
    Si, Yingnan
    Zhang, Jiashuai
    Chen, Kai
    George, Ashley
    Kim, Seulhee
    Zhou, Lufang
    Liu, Xiaoguang
    CANCER RESEARCH, 2024, 84 (22) : 3848 - 3863
12345